Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis

Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - Effect of fingolimod on brain and cognition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44409

Enrollment

Registered

2014-12-17

Start date

2015-02-25

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS Multiple Sclerose

Interventions

MRI, neuropsychological testing and blood sampling.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Subjects should be between 18 and 65 years of age - Subjects should meet the safety criteria to undergo MRI examination - Patients should be diagnosed with RRMS - The first measurement of patients on fingolimod should be within four weeks after the start of fingolimod treatment

Exclusion criteria

Exclusion criteria: - Presence or history of psychiatric or neurological disease (for patients: neurological disease other than MS) that is expected to affect outcome measures (will be discussed with the principal investigator and neurologist) - Presence or history of drug abuse - For patients: relapse or steroid treatment less than four weeks prior to examination - Insufficient visual acuity and motor skills to perform the fMRI task

Design outcomes

Primary

Measure	Time frame
1) Changes in brain activity and brain networks 2) Changes in cognition 3) Progression of physical disability	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)